These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 9604880)
1. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Lampeter EF; Klinghammer A; Scherbaum WA; Heinze E; Haastert B; Giani G; Kolb H Diabetes; 1998 Jun; 47(6):980-4. PubMed ID: 9604880 [TBL] [Abstract][Full Text] [Related]
2. Intervention with nicotinamide in pre-type 1 diabetes: the Deutsche Nikotinamid Interventionsstudie-DENIS. Lampeter EF Diabete Metab; 1993; 19(1 Pt 2):105-9. PubMed ID: 8314411 [TBL] [Abstract][Full Text] [Related]
3. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Greenbaum CJ; Kahn SE; Palmer JP Diabetes; 1996 Nov; 45(11):1631-4. PubMed ID: 8866571 [TBL] [Abstract][Full Text] [Related]
4. Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). European Nicotinamide Diabetes Intervention Trial Group Diabetologia; 2003 Mar; 46(3):339-46. PubMed ID: 12687331 [TBL] [Abstract][Full Text] [Related]
5. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Elliott RB; Chase HP Diabetologia; 1991 May; 34(5):362-5. PubMed ID: 1830860 [TBL] [Abstract][Full Text] [Related]
6. Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes. Cabrera-Rode E; Molina G; Arranz C; Vera M; González P; Suárez R; Prieto M; Padrón S; León R; Tillan J; García I; Tiberti C; Rodríguez OM; Gutiérrez A; Fernández T; Govea A; Hernández J; Chiong D; Domínguez E; Di Mario U; Díaz-Díaz O; Díaz-Horta O Autoimmunity; 2006 Jun; 39(4):333-40. PubMed ID: 16891222 [TBL] [Abstract][Full Text] [Related]
7. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics. Olmos PR; Hodgson MI; Maiz A; Manrique M; De Valdés MD; Foncea R; Acosta AM; Emmerich MV; Velasco S; Muñiz OP; Oyarzún CA; Claro JC; Bastías MJ; Toro LA Diabetes Res Clin Pract; 2006 Mar; 71(3):320-33. PubMed ID: 16233932 [TBL] [Abstract][Full Text] [Related]
8. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Gale EA; Bingley PJ; Emmett CL; Collier T; Lancet; 2004 Mar; 363(9413):925-31. PubMed ID: 15043959 [TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigen identity and DQ risk alleles in autoantibody-positive siblings of children with IDDM are associated with reduced early insulin response. Childhood Diabetes in Finland (DiMe) Study Group. Veijola R; Vähäsalo P; Tuomilehto-Wolf E; Reijonen H; Kulmala P; Ilonen J; Akerblom HK; Knip M Diabetes; 1995 Sep; 44(9):1021-8. PubMed ID: 7657023 [TBL] [Abstract][Full Text] [Related]
10. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270 [TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Pozzilli P; Browne PD; Kolb H Diabetes Care; 1996 Dec; 19(12):1357-63. PubMed ID: 8941464 [TBL] [Abstract][Full Text] [Related]
12. Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Manna R; Migliore A; Martin LS; Ferrara E; Ponte E; Marietti G; Scuderi F; Cristiano G; Ghirlanda G; Gambassi G Br J Clin Pract; 1992; 46(3):177-9. PubMed ID: 1286017 [TBL] [Abstract][Full Text] [Related]
13. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Bingley PJ; Gale EA; Diabetologia; 2006 May; 49(5):881-90. PubMed ID: 16514546 [TBL] [Abstract][Full Text] [Related]
14. Islet cell antibodies are less predictive of IDDM among unaffected children in the general population than in sibs of children with diabetes. The Childhood Diabetes in Finland Study Group. Knip M; Karjalainen J; Akerblom HK Diabetes Care; 1998 Oct; 21(10):1670-3. PubMed ID: 9773728 [TBL] [Abstract][Full Text] [Related]
15. On the sequential design of the Deutsche Nikotinamid Interventionsstudie--DENIS. Haastert B; Giani G Diabete Metab; 1993; 19(1 Pt 2):100-4. PubMed ID: 8314410 [TBL] [Abstract][Full Text] [Related]
16. Validity of screening for individuals at risk for type I diabetes by combined analysis of antibodies to recombinant proteins. Christie MR; Roll U; Payton MA; Hatfield EC; Ziegler AG Diabetes Care; 1997 Jun; 20(6):965-70. PubMed ID: 9167107 [TBL] [Abstract][Full Text] [Related]
17. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Pozzilli P; Visalli N; Signore A; Baroni MG; Buzzetti R; Cavallo MG; Boccuni ML; Fava D; Gragnoli C; Andreani D Diabetologia; 1995 Jul; 38(7):848-52. PubMed ID: 7556988 [TBL] [Abstract][Full Text] [Related]
18. Risk of type 1 diabetes development in children with incidental hyperglycemia: A multicenter Italian study. Lorini R; Alibrandi A; Vitali L; Klersy C; Martinetti M; Betterle C; d'Annunzio G; Bonifacio E; Diabetes Care; 2001 Jul; 24(7):1210-6. PubMed ID: 11423504 [TBL] [Abstract][Full Text] [Related]
19. High proinsulin levels in late PRE-IDDM stage. Rodríguez-Villar C; Conget I; Casamitjana R; Vidal J; Manzanares JM; Gomis R Diabetes Res Clin Pract; 1997 Aug; 37(2):145-8. PubMed ID: 9279485 [TBL] [Abstract][Full Text] [Related]
20. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. Elliott RB; Pilcher CC; Fergusson DM; Stewart AW J Pediatr Endocrinol Metab; 1996; 9(5):501-9. PubMed ID: 8961125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]